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Abstract
Background: Primary renal well-differentiated neuroendocrine tumors (WDNETs) also called carcinoid and atypical
carcinoid are extremely rare, and little is known about parameters that may predict prognosis at diagnosis.
Methods: Six cases of primary renal WDNET were collected. After reviewing slides stained with hematoxylin and
eosin, proportions of each growth pattern were determined. Synaptophysin, chromogranin, CD56, and Ki-67
immunostaining and Ki-67 morphometric analysis were performed.
Results: Patients included three female and three males, mean age was 53.3 years. The mean tumor size was 4.5
cm, three cases were greater than 5 cm. At the time of initial surgery, lymph node and/or distant metastasis was
confirmed in two cases. In a third case, no metastasis was initially found, but lymph node metastasis was identified
during follow-up. The remaining three cases did not exhibit metastasis. Histopathologically, the renal WDNETs were
primarily composed of ribbon-like and sheet-like growth patterns. Most of the tumors were diffusely positive for
neuroendocrine markers. Mitotic count was high (≥2/10HPF) in cases with lymph node or distant metastasis but
was low (< 2/10HPF) in non-metastatic cases. Furthermore, the Ki-67 index was also higher (≥3%) in the cases with
metastases than in cases without metastasis.
Conclusion: Three out of the six primary renal WDNETs demonstrated aggressive behavior and exhibited increased
mitotic counts and Ki-67 indices. These results suggest that mitosis and the Ki-67 index could be used as
prognostic indicators for renal WDNET.
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Background
Neuroendocrine tumors (NET) can occur anywhere in
the human body, but in more than 90% of cases, they
are found in the gastrointestinal tract or the respiratory
tract [1]. NETs in the genitourinary system are only
found in very small numbers, and primary renal NET is
extremely rare [2].
Primary renal NETs consist of well-differentiated neuroen-
docrine tumors (WDNET) and high grade neuroendocrine
carcinomas [3]. High grade neuroendocrine carcinomas can
be classified into large cell neuroendocrine carcinoma and
small cell neuroendocrine carcinoma, according to their
histopathologic features. These disease entities present with
extensive necrosis and abundant mitotic figures [4–6].
Primary renal WDNET is a disease entity that histo-
pathologically shows hardly any necrosis and exhibits as
low mitotic figures [7]. It has an indolent clinical course
but occasionally has lymph node metastasis at surgery,
subsequently progressing to metastatic disease [8].
WDNET frequently occurs in relation to congenital
renal diseases, such as a horseshoe kidney or renal
teratomas [9, 10]. Primary renal WDNETs have very low
incidence, with fewer than 100 reported cases [11].
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NETs in other organs are classified into three grades
that provide significant prognostic information [12]. The
World Health Organization (WHO) classifies gastroen-
teropancreatic NETs having fewer than 2 mitoses/10
high power field (HPF) and a Ki-67 index lower than 3% as
low grade, those with 2 to 20 mitoses/10 HPF or a Ki-67
index between 3 and 20% as intermediate, and those with
greater than 20 mitoses/10 HPF or a Ki-67 index of greater
than 20% as high grade. Lung and thymus NETs with fewer
than 2 mitoses/10 HPF in the absence of necrosis are classi-
fied as low grade, those with 2 to 10 mitoses/10 HPF or foci
of necrosis are classified as intermediate, and those with
more than 10 mitoses/10 HPF are classified as high grade
[13]. However, in primary renal WDNETs, little is known
about the prognostic parameters.
In this study, we report six primary renal WDNET
cases with histopathologic characteristics and prolifera-
tive activity.
Methods
Case selection and histopathological review
We searched the computerized database of the Department
of Pathology, Seoul National University Hospital and found
six cases that diagnosed with primary renal carcinoid or
well-differentiated NET between 2005 and 2016. Four cases
underwent radical nephrectomy at Seoul National University
Hospital, and two cases (case no. 5 and no. 6) were consult-
ation cases. Primary renal mass was detected by abdominal
computed tomography and/or magnetic resonance imaging.
We reviewed hematoxylin and eosin (H&E)-stained slides to
confirm the diagnosis and to identify various histological
parameters, including mitotic activity, the proportion of
growth patterns, and tumor local extension. We collected
the clinical data and pathologic information from the
medical records and pathology reports.
This study was approved by the institutional review
board of Seoul National University Hospital.
Immunohistochemistry and morphometric analysis
Immunohistochemical staining for Ki-67 (MIB-1, Dako,
Glostrup, Denmark), CD56 (123C3.D5, Cell Marque, Rock-
lin, CA), synaptophysin (27G12, Novocastra, Newcastle, UK)
and chromogranin (5H7, Leica Biosystems, Newcastle, UK)
was performed using the Ventana Benchmark XT automated
staining system (Ventana Medical Systems, Tucson, AZ).
Morphometric analysis of Ki-67 immunostaining was
performed in primary and metastatic lesions for accurate
measurement. All stained slides were scanned at 400x
absolute magnification using the Aperio scanning system
(Aperio Technologies; Vista, CA). Acquired digital path-
ology slide images were viewed and analyzed with Image-
Scope analysis software (version 12; Aperio Technologies,
Inc.). The whole slide was examined, and an area was con-
sidered acceptable for analysis if it contained 500–1000
tumor cells. The Ki-67 index is the ratio of the number of
tumor cells with positive nuclear Ki-67 staining to the
total number of tumor cells in a designated area. Three
areas with the highest positive nuclear staining cell ratio
were designated as hot spot areas. These areas were then




The clinicopathologic features of six primary renal
WDNET cases are summarized in Table 1.
None of the six cases exhibited other renal malforma-
tions or diseases and were diagnosed incidentally with-
out any tumor-associated signs or symptoms. The mean
age of the patients was 53.3 years; three patients were
female, while three were male. All six cases underwent
radical nephrectomy. Clinical follow-up periods ranged
from one to 17 years (average, 95 months). At the time
of initial surgery, four cases did not show any additional
mass on abdominal computed tomography, magnetic
resonance imaging or positron emission tomography,
and two cases showed multiple small liver or bone nod-
ules. Thus, all six cases were consistent with primary
renal tumor. Case no. 4 exhibited liver and lymph node
metastases at the time of initial surgery. Case no. 5 did
not present with metastasis at the time of initial surgery,
but lymph node metastasis was identified 15 years later.
Case no. 6 exhibited both liver and bone metastases at
the time of initial surgery. The remaining three cases
Table 1 Clinicopathologic characteristics of primary renal well-differentiated neuroendocrine tumors
Case Age/sex Location Initial TNM stage Tumor size (cm) Metastasis at
initial surgery




1 54/F Mid-kidney Confined to the kidney 3.8 No No NED (11 yr. 11 mo)
2 47/F Mid-kidney Confined to the kidney 2.4 No No NED (7 yr. 2 mo)
3 60/F Lower pole Confined to the kidney 1.3 No No NED (6 yr. 4 mo)
4 52/M Mid-kidney Extension renal sinus fat 5.4 Liver & lymph node No AWD (3 yr. 6 mo)
5 59/M Not stated Confined to the kidney 5.7 No Lymph node (60mo) NED (17 yr. 1 mo)
6 48/M Lower pole Confined to the kidney 8.1 Liver & bone Liver & bone (3mo) AWD (1 yr. 11 mo)
AWD alive with disease, mo months, NED no evidence of disease, RN radical nephrectomy, yr. years
Kim et al. Diagnostic Pathology           (2019) 14:12 Page 2 of 6
exhibited no metastasis through the time of this study.
Case no. 4 underwent preoperative transarterial che-
moembolization (TACE) once and postoperative TACE
twice. Case no. 5 underwent lymph node dissection.
Case no. 6 underwent postoperative TACE three times
and radiation therapy for the treatment of bone metasta-
sis. Two of the six patients exhibiting synchronous
metastases are still alive with disease. The remaining
four patients are still alive with no evidence of disease.
All tumors were solitary single masses. Tumor size
ranged from 1.3 to 8.1 cm (average, 4.5 cm). Tumor size in
all three cases with metastases were greater than 5 cm,
and of the three cases without metastasis, tumors were all
smaller than 4 cm. The primary tumors in the three cases
without metastasis were confined to the renal paren-
chyma, and extension to the renal sinus fat was observed
in one case with lymph node and liver metastases (Fig. 1).
Microscopic examination revealed that histologic fea-
tures of primary renal WDNET were similar to WDNET
in other organs. Monotonous tumor cells have scant to
moderate amounts of eosinophilic to clear cytoplasm.
Nuclei are round to ovoid with inconspicuous nucleoli
and a “salt and pepper” chromatin pattern [16]. Five
cases showed a predominantly ribbon-like growth pat-
tern. The remaining case revealed mixed ribbon-like
(25%) and sheet-like (75%) growth patterns, and this
case had lymph node and liver metastases at the time of
initial surgery (Fig. 2a, b). Numerous apoptotic bodies
were also observed in case no. 4 (Fig. 2c). None of the
six cases exhibited any necrosis. Synaptophysin expres-
sion was positive in all six cases, chromogranin expres-
sion and CD56 expression were positive in five and
three cases, respectively (Table 2 and Fig. 2d).
Proliferative indices
Mitotic figures were found in cases with lymph node or
distant metastasis, while cases without metastasis did
not exhibited mitotic figures (Table 3 and Fig. 3a).
Metastatic lesions in three cases (case no. 4, 5, and 6)
also revealed mitotic figures (Table 3).
Results of morphometric analysis are summarized in
Tables 3 and 4. Among the three cases with lymph node
or distant metastasis, the Ki-67 index of primary lesions
was high (≥3%) in two cases and low (< 3%) in one case
(Fig. 3b). All three cases without metastasis had a cor-
respondingly low (< 3%) Ki-67 index, while the Ki-67
index of metastatic lesions was also high (≥3%) in all
three cases. The average values of mitotic counts and
the Ki-67 index were greater in the primary and meta-
static lesions of the three cases with metastases than in
the primary lesions of the three cases without metastasis
(Table 4).
Discussion
Renal neuroendocrine tumors are classified into primary
renal WDNETs and neuroendocrine carcinomas. Pri-
mary renal WDNET includes typical and atypical carcin-
oid tumors, and neuroendocrine carcinoma includes
small cell and large cell neuroendocrine carcinomas
[17]. These entities are all International Classification of
Diseases for Oncology (ICD-O) behavior 3 code [3]. Pri-
mary renal WDNET is known to have distinct histo-
pathological and clinical characteristics, distinct from
high-grade neuroendocrine carcinoma [18]. However,
little is known about prognostic indicators of tumor ag-
gressiveness, such as lymph node or distant metastasis.
In this study, six cases of surgically resected primary
renal WDNET were analyzed. Lymph node or distant
metastasis was confirmed in three cases, two of which
presented with metastases at the time of initial nephrec-
tomy. Case no. 4 showed lymph node and liver metasta-
ses, and case no. 6 showed liver and bone metastases.
These two cases with synchronous metastases showed 3
and 6 mitoses/10 HPF on H&E staining, respectively, as
well as high Ki-67 indices. Case no. 5 did not show me-
tastasis at the time of initial surgery, but retroperitoneal
Fig. 1 One case exhibited extension to the renal sinus fat on gross finding (a) and microscopic finding (b, × 40)
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lymph node metastasis was found 15 years later. In this
case, the primary renal lesion showed 1 mitosis/10 HPF
on H&E staining and a low Ki-67 index, comparable to
the three cases lacking metastasis. All metastatic lesions
in case no. 4, 5, and 6 showed high mitotic counts and
high Ki-67 indices.
Currently, there is no established grading system for
renal NET. However, according to the WHO classifica-
tion, gastroenteropancreatic, lung, and thymic NETs are
classified into low, intermediate and high grades [13].
If the grading system for gastroenteropancreatic NETs
was applied to our six cases, two cases (case no. 4 and 6)
showing synchronous metastasis would be classified as
NET grade 2 due to a high mitotic rate and Ki-67 index.
In case no. 5, with non-synchronous lymph node metas-
tasis, the primary renal lesion would be classified as
NET grade 1, and the metastatic lymph node lesion
would be classified as NET grade 2. The three cases
without metastasis would be classified as NET grade 1. If
the grading system for lung and thymic NETs was ap-
plied, two cases (case no. 4 and 6) showing synchronous
metastasis would be classified as atypical carcinoid. In
case no. 5, with non-synchronous lymph node metasta-
sis, the primary renal lesion would be classified as typical
carcinoid, and the metastatic lymph node lesion would
be classified as atypical carcinoid. The three cases with-
out metastasis would be classified as typical carcinoid.
The prognostic value of mitosis and/or the Ki-67 index in
gastroenteropancreatic NETs has been well studied [19]. A
Fig. 2 Histologic features of case with lymph node and liver metastasis. Mixed ribbon-like (a, × 200) and sheet-like (b, × 200) patterns are
observed. Also many apoptotic bodies are observed (c, × 400). Synaptophysin showed diffuse positive staining (d, × 400)
Table 2 Immunohistochemical staining of neuroendocrine
markers
Case Synaptophysin Chromogranin CD56
1 P P N
2 P Focal P P
3 P Focal P N
4 P Focal P Focal P
5 P Focal P N
6 P N P
Focal P focal positive, N negative, P positive;
Table 3 Histologic growth pattern, mitosis and Ki-67
morphometric analysis (Automated counting by analyzer)
Case Growth pattern:
sheet-like/ribbon-like (%)
Mitoses (/10HPF) Ki-67 index (%)
1 (primary) 3/97 0 0.51
2 (primary) 3/97 0 1.24
3 (primary) 3/97 0 0.6
4 (primary) 75/25 3 8.27
4 (LN) 20/80 2 3.22
5 (primary) 5/95 1 0.66
5 (LN) 5/95 2 3.3
6 (primary) 1/99 6 13.51
6 (Liver) 1/99 4 17.79
HPF high power field, Primary radical nephrectomy specimen, Liver liver biopsy
specimen, LN lymph node dissection specimen
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multi-institutional study reported a positive correlation be-
tween the risk of lymph node metastasis and grade in neu-
roendocrine tumors of the large intestine [20].
Currently, there are no well-defined grading systems
in use for renal NET and only a few studies regarding
prognostic indicators of primary renal WDNET have
been published. Aung et al. reported eleven cases of pri-
mary renal neuroendocrine tumors, of which only two
cases with liver metastases showed a Ki-67 index of 3
and 5%. They could be classified as NET grade 2, atyp-
ical carcinoid, according to WHO classification of lung
and thymus tumors. The authors suggested that high
proliferative rate could indicate poor outcome [16].
Hansel et al. reported 21 cases of primary renal carcin-
oid tumor. The case with the highest mitotic figures (4
mitoses/10 HPF) had liver and bone metastases at the
time of initial surgery and died of disease eight months
later [21]. Raslan et al. suggested that tumor stage, cellu-
lar atypia and mitotic figures are likely to correlate with
patient outcome [22]. Romero et al. suggested that mi-
totic figure higher than 1/10 HPF may be related to poor
outcome, and tumors of less than 4 cm in size, which are
confined to the renal parenchyma, may be related to
lower rates of metastasis [1].
In this study, we also revealed that renal WDNETs
with metastasis exhibited the higher mitotic counts and
Ki-67 indices than those without metastasis. Further-
more, tumor size of the three cases with metastases were
greater than 5 cm, while tumor size of the three cases
without metastasis were less than 4 cm. A case with ex-
tension to the renal sinus fat also presented with lymph
node and liver metastases. These results suggested that
mitotic count, Ki-67 index and tumor size can be useful
prognostic indicators in primary renal WDNET.
Conclusion
In summary, a higher proliferative activity of primary
renal WDNET, including mitotic counts and the Ki-67
Fig. 3 Proliferative indices in cases with metastasis. Mitotic figures (a, case no. 4, × 400; b, case no. 6, × 400) and Ki-67 immunostaining (c, case no. 4,
× 400; d, case no. 6, × 400) were observed
Table 4 Comparison of proliferative indices between non-metastatic & metastatic cases
Case Average mitoses (/10HPF) Average Ki-67 index (%)
Non-metastatic cases 0 1.12
Metastatic cases (primary lesion) 3.33 7.48
Metastatic cases (metastatic lesion) 2.67 8.1
HPF high power field
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index, appears to correlate with the risk of metastasis.
The results of our study, in accordance with previous
studies, suggest that a grading system based on mitotic
counts and the Ki-67 index may be a good candidate for
predicting the aggressiveness of primary renal WDNET.
Further analysis of a greater number of cases of primary
renal WDNET is needed to determine the most appro-
priate prognostic parameters.
Abbreviations
H&E: Hematoxylin and eosin; HPF: High power field; ICD-O: International
Classification of Diseases for Oncology; NET: Neuroendocrine tumor;
TACE: Transarterial chemoembolization; WDNET: Well-differentiated




This work was supported by grant 04–2016-0460 from the Seoul National
University Hospital Research Fund.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
MKC designed the study and performed histological examination of the
tumors. KHS performed histological analysis. KBH evaluated the
immunohistochemical staining, performed the morphometric analysis, and
drafted the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Seoul National
University Hospital (reference number H-1609-103793). Obtaining additional
informed consent for the use of patient samples was not required, as determined




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Pathology, Seoul National University College of Medicine,
Seoul, Republic of Korea. 2Department of Pathology, Inje University College
of Medicine, Goyang, Republic of Korea.
Received: 13 November 2018 Accepted: 1 February 2019
References
1. Romero FR, Rais-Bahrami S, Permpongkosol S, Fine SW, Kohanim S, Jarrett
TW. Primary carcinoid tumors of the kidney. J Urol. 2006;176:2359–66.
2. Chen CT, Hsieh SW, Hsieh TS. Case report: a case of primary renal carcinoid
tumor. Urol Case Rep. 2018;21:14–6.
3. WHO Classification of Tumours of the Urinary System and Male Genital
Organs. Lyon: International Agency for Research on Cancer 2016.
4. Quinn AM, Blackhall F, Wilson G, Danson S, Clamp A, Ashcroft L, Brierley J,
Hasleton P. Extrapulmonary small cell carcinoma: a clinicopathological study with
identification of potential diagnostic mimics. Histopathology. 2012;61:454–64.
5. Lane BR, Chery F, Jour G, Sercia L, Magi-Galluzzi C, Novick AC, Zhou M. Renal
neuroendocrine tumours: a clinicopathological study. BJU Int. 2007;100:1030–5.
6. Gonzalez-Lois C, Madero S, Redondo P, Alonso I, Salas A, Angeles
Montalban M. Small cell carcinoma of the kidney: a case report and review
of the literature. Arch Pathol Lab Med. 2001;125:796–8.
7. Omiyale AO, Venyo AK. Primary carcinoid tumour of the kidney: a review of
the literature. Adv Urol. 2013;2013:–579396.
8. Tal R, Lask DM, Livne PM. Metastatic renal carcinoid: case report and review
of the literature. Urology. 2003;61:838.
9. Begin LR, Guy L, Jacobson SA, Aprikian AG. Renal carcinoid and horseshoe
kidney: a frequent association of two rare entities--a case report and review
of the literature. J Surg Oncol. 1998;68:113–9.
10. Krishnan B, Truong LD, Saleh G, Sirbasku DM, Slawin KM. Horseshoe kidney
is associated with an increased relative risk of primary renal carcinoid tumor.
J Urol. 1997;157:2059–66.
11. Teegavarapu PS, Rao P, Matrana M, Cauley DH, Wood CG, Tannir NM.
Neuroendocrine tumors of the kidney: a single institution experience. Clin
Genitourin Cancer. 2014;12:422–7.
12. Tominaga K, Nakanishi Y, Nimura S, Yoshimura K, Sakai Y, Shimoda T.
Predictive histopathologic factors for lymph node metastasis in patients
with nonpedunculated submucosal invasive colorectal carcinoma. Dis Colon
Rectum. 2005;48:92–100.
13. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic
classification of neuroendocrine tumors: a review of nomenclature, grading,
and staging systems. Pancreas. 2010;39:707–12.
14. Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS,
Borgquist S, Chang MC, Dodson A, et al. Analytical validation of a
standardized scoring protocol for Ki67: phase 3 of an international
multicenter collaboration. NPJ Breast Cancer. 2016;2:–16014.
15. Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, Balci S, Gucer
H, Jang KT, Tajiri T, et al. Calculation of the Ki67 index in pancreatic
neuroendocrine tumors: a comparative analysis of four counting
methodologies. Mod Pathol. 2015;28:686–94.
16. Aung PP, Killian K, Poropatich CO, Linehan WM, Merino MJ. Primary
neuroendocrine tumors of the kidney: morphological and molecular
alterations of an uncommon malignancy. Hum Pathol. 2013;44:873–80.
17. Kuroda N, Imamura Y, Hamashima T, Ohe C, Mikami S, Nagashima Y, Inoue
K, Perez-Montiel D, Petersson F, Michal M, Hes O. Review of small cell
carcinoma of the kidney with focus on clinical and pathobiological aspects.
Pol J Pathol. 2014;65:15–9.
18. Korkmaz T, Seber S, Yavuzer D, Gumus M, Turhal NS. Primary renal carcinoid:
treatment and prognosis. Crit Rev Oncol Hematol. 2013;87:256–64.
19. Gastrointestinal Pathology Study Group of Korean Society of P, Cho MY,
Sohn JH, Jin SY, Kim H, Jung ES, Kim MJ, Kim KM, Kim WH, Kim JM, et al:
proposal for a standardized pathology report of gastroenteropancreatic
neuroendocrine tumors: prognostic significance of pathological parameters.
Korean J Pathol 2013, 47:227–237.
20. Kojima M, Ikeda K, Saito N, Sakuyama N, Koushi K, Kawano S, Watanabe T,
Sugihara K, Ito M, Ochiai A. Neuroendocrine tumors of the large intestine:
Clinicopathological features and predictive factors of lymph node
metastasis. Front Oncol. 2016;6:173.
21. Hansel DE, Epstein JI, Berbescu E, Fine SW, Young RH, Cheville JC. Renal carcinoid
tumor: a clinicopathologic study of 21 cases. Am J Surg Pathol. 2007;31:1539–44.
22. Raslan WF, Ro JY, Ordonez NG, Amin MB, Troncoso P, Sella A, Ayala AG.
Primary carcinoid of the kidney. Immunohistochemical and ultrastructural
studies of five patients. Cancer. 1993;72:2660–6.
Kim et al. Diagnostic Pathology           (2019) 14:12 Page 6 of 6
